Back to Journals » Breast Cancer: Targets and Therapy » Volume 8

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

Authors Ieni A, Barresi V, Ricciardi GRR, Adamo B, Adamo V, Tuccari G

Received 25 May 2016

Accepted for publication 20 June 2016

Published 19 August 2016 Volume 2016:8 Pages 157—159

DOI https://doi.org/10.2147/BCTT.S113577

Checked for plagiarism Yes

Editor who approved publication: Professor Pranela Rameshwar


Antonio Ieni,1 Valeria Barresi,1 Giuseppina Rosaria Rita Ricciardi,2 Barbara Adamo,3 Vincenzo Adamo,2 Giovanni Tuccari1

1Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU “Policlinico G Martino”; 2Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology of Adult And Evolutive Age “Gaetano Barresi”, University of Messina, Messina, Italy; 3Medical Oncology Hospital Clinic, Barcelona, Spain

Recently, we read with great interest the review by Collignon et al entitled “Triplenegative breast cancer: treatment challenges and solutions”,1 which appeared in the last issue of Breast Cancer: Targets and Therapy. In this article, the authors extensively reviewed studies concerning the opportunity to identify triple negative breast carcinoma (TNBC) subtypes by newly proposed markers, taking into account their biological heterogeneity on the light of clinical implications.

View original paper by Collignon et al.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]